PMID- 35953408
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20220915
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 83
IP  - 10
DP  - 2022 Oct
TI  - HLA homozygosity is associated with Non-Hodgkin lymphoma.
PG  - 730-735
LID - S0198-8859(22)00151-3 [pii]
LID - 10.1016/j.humimm.2022.08.002 [doi]
AB  - The "heterozygote advantage" hypothesis has been postulated regarding the role of 
      human leukocyte antigen (HLA) in non-Hodgkin lymphoma (NHL), where homozygous 
      loci are associated with an increased risk of disease. In this retrospective 
      study, we analyzed the HLA homozygosity of 3789 patients with aplastic anemia 
      (AA), acute lymphocytic leukemia (ALL), acute myeloblastic leukemia (AML), 
      chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), 
      myelodysplastic syndrome (MDS), multiple myeloma (MM), and non-Hodgkin lymphoma 
      (NHL) at HLA-A, B, C, DRB1 and DQB1 loci compared to 169,964 normal controls. HLA 
      homozygosity at one or more loci was only associated with an increased risk in 
      NHL patients (OR = 1.28, 95% CI [1.09, 1.50], p = 0.002). This association was 
      not seen in any of the other hematologic diseases. Homozygosity at HLA-A alone, 
      HLA-B + C only, and HLA-DRB1 + DQB1 only was also significantly associated with 
      NHL. Finally, we observed a 17% increased risk of NHL with each additional 
      homozygous locus (OR per locus = 1.17, 95% CI [1.08, 1.25], p 
      trend = 2.4 x 10(-5)). These results suggest that reduction of HLA diversity 
      could predispose individuals to an increased risk of developing NHL.
CI  - Copyright (c) 2022 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Roark, Christina L
AU  - Roark CL
AD  - ClinImmune Cell and Gene Therapy, Aurora, CO, USA; Division of Allergy and 
      Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, 
      USA. Electronic address: christina.roark@cuanschutz.edu.
FAU - Ho, Bethany E
AU  - Ho BE
AD  - University of Colorado School of Medicine, Aurora, CO, USA.
FAU - Aubrey, Michael T
AU  - Aubrey MT
AD  - ClinImmune Cell and Gene Therapy, Aurora, CO, USA; Division of Allergy and 
      Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, 
      USA.
FAU - Anobile, Cheri
AU  - Anobile C
AD  - ClinImmune Cell and Gene Therapy, Aurora, CO, USA.
FAU - Israeli, Sapir
AU  - Israeli S
AD  - Department of Mathematics, Bar-Ilan University, Ramat Gan, Israel.
FAU - Phang, Tzu L
AU  - Phang TL
AD  - Department of Biomedical Informatics, University of Colorado Anschutz Medical 
      Campus, Aurora, CO, USA.
FAU - Braxton, Danielle
AU  - Braxton D
AD  - ClinImmune Cell and Gene Therapy, Aurora, CO, USA.
FAU - Ho, Andrea P
AU  - Ho AP
AD  - University of Colorado School of Medicine, Aurora, CO, USA.
FAU - Freed, Brian M
AU  - Freed BM
AD  - ClinImmune Cell and Gene Therapy, Aurora, CO, USA; Division of Allergy and 
      Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20220808
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-A Antigens)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - HLA-A Antigens
MH  - Histocompatibility Antigens
MH  - Histocompatibility Antigens Class I
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - *Lymphoma, Non-Hodgkin/genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - HLA antigens
OT  - Homozygosity
OT  - Non-Hodgkin lymphoma
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/12 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/08/11 22:06
PHST- 2022/03/10 00:00 [received]
PHST- 2022/08/01 00:00 [revised]
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/08/12 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/08/11 22:06 [entrez]
AID - S0198-8859(22)00151-3 [pii]
AID - 10.1016/j.humimm.2022.08.002 [doi]
PST - ppublish
SO  - Hum Immunol. 2022 Oct;83(10):730-735. doi: 10.1016/j.humimm.2022.08.002. Epub 
      2022 Aug 8.